BMRN Q1 2021 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$486M-3.2% YoY

Gross Profit

$366M75.3% margin

Operating Income

$25M5.2% margin

Net Income

$17M3.6% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$114M

Free Cash Flow

$85M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$5.8B

Total Liabilities

$1.6B

Stockholders' Equity

$4.2B

Cash & Equivalents

$667M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$486M	$502M	-3.2%
Gross Profit	$366M	$391M	-6.3%
Operating Income	$25M	$105M	-76.1%
Net Income	$17M	$81M	-78.7%

Revenue Segments

Royalty And Other

$18M100%

Geographic Segments

UNITED STATES

$208M43%

Europe

$162M33%

Latin America

$60M12%

Rest Of World

$56M12%